Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/62534
SAFETY AND IMMUNOGENICITY OF AN IN VIVO MUSCLE ELECTROPORATION DELIVERY SYSTEM FOR DNA- HSP65 TUBERCULOSIS VACCINE IN CYNOMOLGUS MONKEYS
Author
Lima, Monique Ribeiro de
Leandro, Ana Cristina C. S.
Souza, Andreia Lamoglia de
Barradas, Marcio Mantuano
Roma, Eric Henrique
Fernandes, Ana Teresa Gomes
Galdino-Silva, Gabrielle
Carvalho, Joyce Katiuccia M. Ramos
Marchevsky, Renato Sergio
Coelho, Janice M. C. Oliveira
Gonçalves, Eduardo Dantas Casillo
VandeBerg, John L.
Silva, Celio Lopes
Bonecini-Almeida, Maria da Gloria
Leandro, Ana Cristina C. S.
Souza, Andreia Lamoglia de
Barradas, Marcio Mantuano
Roma, Eric Henrique
Fernandes, Ana Teresa Gomes
Galdino-Silva, Gabrielle
Carvalho, Joyce Katiuccia M. Ramos
Marchevsky, Renato Sergio
Coelho, Janice M. C. Oliveira
Gonçalves, Eduardo Dantas Casillo
VandeBerg, John L.
Silva, Celio Lopes
Bonecini-Almeida, Maria da Gloria
Affilliation
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil / Division of Human Genetics. South Texas Diabetes and Obesity Institute. The University of Texas Rio Grande Valley. Brownsville, TX, USA.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Institute of Biotechnology in Immunobiologicals. Laboratory of Neurovirulence. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Pathology. Rio de Janeiro, RJ, Brazil.
Farmacore Biotecnologia Ltda. Ribeirão Preto, SP, Brazil.
Division of Human Genetics. South Texas Diabetes and Obesity Institute. The University of Texas Rio Grande Valley. Brownsville, TX, USA.
Farmacore Biotecnologia Ltda. Ribeirão Preto, SP, Brazil / University of São Paulo. School of Medicine of Ribeirão Preto. Laboratory for Research and Development of Immunobiologicals. Ribeirão Preto, SP, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil / Division of Human Genetics. South Texas Diabetes and Obesity Institute. The University of Texas Rio Grande Valley. Brownsville, TX, USA.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Institute of Biotechnology in Immunobiologicals. Laboratory of Neurovirulence. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Pathology. Rio de Janeiro, RJ, Brazil.
Farmacore Biotecnologia Ltda. Ribeirão Preto, SP, Brazil.
Division of Human Genetics. South Texas Diabetes and Obesity Institute. The University of Texas Rio Grande Valley. Brownsville, TX, USA.
Farmacore Biotecnologia Ltda. Ribeirão Preto, SP, Brazil / University of São Paulo. School of Medicine of Ribeirão Preto. Laboratory for Research and Development of Immunobiologicals. Ribeirão Preto, SP, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Laboratory of Immunology and Immunogenetic in Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Abstract
A Bacille Calmette–Guérin (BCG) is still the only licensed vaccine for the prevention of tuberculosis, providing limited protection against Mycobacterium tuberculosis infection in adulthood. New advances in the delivery of DNA vaccines by electroporation have been made in the past decade. We evaluated the safety and Immunogenicity of the DNA-hsp65 vaccine administered by intramuscular electroporation (EP) in cynomolgus macaques. Animals received three doses of DNA-hsp65 at 30-day intervals. We demonstrated that intramuscular electroporated DNA-hsp65 vaccine immunization of cynomolgus macaques was safe, and there were no vaccine-related effects on hematological, renal, or hepatic profiles, compared to the pre-vaccination parameters. No tuberculin skin test conversion nor lung X-ray alteration was identified. Further, low and transient peripheral cellular immune response and cytokine expression were observed, primarily after the third dose of the DNA-hsp65 vaccine. Electroporated DNA-hsp65 vaccination is safe but provides limited enhancement of peripheral cellular immune responses. Preclinical vaccine trials with DNA-hsp65 delivered via EP may include a combination of plasmid cytokine adjuvant and/or protein prime–boost regimen, to help the induction of a stronger cellular immune response.
Share